Search

A study conducted by researchers at Oregon Health & Science University (OHSU) aimed to evaluate the effectiveness of Draf 3 frontal sinusotomy in patients with refractory chronic rhinosinusitis with nasal polyposis (CRSwNP). The study found that Draf 3 surgery led to significant improvement in disease severity up to 24 months postoperative, as measured by the sinonasal outcomes test (SNOT-22). Only 14.9% of patients required rescue with the drug dupilumab, with patients who had aspirin-exacerbated respiratory disease (AERD) being more likely to require rescue. The study suggests that Draf 3 surgery can be an effective treatment option for CRSwNP, with the majority of patients avoiding the need for dupilumab therapy. [Extracted from the article]

A systematic review conducted by researchers at the University of Granada in Spain examined the use of omalizumab and dupilumab in the treatment of bullous pemphigoid (BP), an autoimmune disease characterized by blistering skin. The review analyzed 61 studies involving 886 patients and found that both drugs were effective in improving symptoms of BP and had minimal side effects. However, the researchers noted that the quality of the included studies was limited, and called for future studies with higher scientific evidence. Overall, omalizumab and dupilumab were deemed safe and viable treatment options for BP patients who did not respond to other therapies. [Extracted from the article]

Researchers at the University of Szeged in Hungary have conducted a study on the real-life effectiveness of dupilumab in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The study included 135 adult patients with uncontrolled CRSwNP who received dupilumab treatment. After 6 and 12 months of treatment, significant improvements were observed in all clinical parameters, and no severe side effects or need for rescue treatment were reported. The researchers concluded that continuous dupilumab treatment is effective and safe in daily clinical practice for CRSwNP and other type 2 comorbidities. [Extracted from the article]

The article focuses on the use of dupilumab in patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, with topics including phase 3 clinical trial results, lung function, and exacerbations. It study found that dupilumab reduced the rate of moderate or severe exacerbations and improved lung function in patients with COPD and type 2 inflammation, making it a potential treatment option for this population.

The article focuses on the effectiveness of dupilumab in treating eosinophilic esophagitis in children aged 1 to 11. Topics include the trial design comparing high and low doses of dupilumab to a placebo, the significant improvements in histologic, endoscopic, and transcriptomic measures with dupilumab, and the adverse events associated with the treatment.

A recent study conducted by researchers from the University of Rochester Medical Center has found that dupilumab, a drug used to treat moderate to severe atopic dermatitis (AD), is safe and effective for long-term use. The study, which lasted for 5 years and involved over 2,600 adult patients, showed that the drug led to significant improvements in symptoms and quality of life for the majority of participants. Common side effects included nasopharyngitis, worsening AD, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site reaction. These findings suggest that dupilumab could be a valuable treatment option for individuals with moderate to severe AD. [Extracted from the article]

A recent report discusses research on severe asthma, which remains a challenging condition to manage. The most common phenotype in children and adolescents with severe asthma is type 2 inflammation. Anti-inflammatory drugs, such as corticosteroids, are typically used to reduce type 2 inflammation, but some patients may require high doses without achieving asthma control. Dupilumab, a monoclonal antibody, has been approved for pediatric severe type 2 asthma and has shown promising results in reducing asthma exacerbations, corticosteroid use, and improving lung function and quality of life. However, careful phenotyping is necessary to identify the ideal candidates for this treatment. [Extracted from the article]

A study conducted at the University Hospital of Montpellier in France examined the response of patients with moderate to severe atopic dermatitis (AD) who did not respond adequately to the standard dose of dupilumab, a medication used to treat AD. The study included adult patients who were subsequently treated with an increased dose of dupilumab or a combination of dupilumab with other medications. The results showed that 68.75% of the patients achieved an improved response, with 45.8% experiencing a complete response. No specific strategy was found to be significantly better than others. The study suggests that increasing the dose of dupilumab or combining it with other medications could be alternative and safe options for patients who do not respond to the standard treatment. Further research is needed to evaluate the effectiveness and cost-effectiveness of these approaches. [Extracted from the article]

A recent case report from Hopitaux Universitaires de Strasbourg in France discusses a patient with atypical alveolar echinococcosis, a parasitic disease caused by Echinococcus multilocularis. The patient, an 82-year-old who was immunocompromised due to corticosteroid therapy and treatment with dupilumab, presented with hepatic and pulmonary lesions. The researchers highlight the importance of considering alveolar echinococcosis in cases of systemic disease with hepatic and pulmonary involvement, particularly in immunocompromised patients. The role of dupilumab in the disease's progression and atypical presentation is also discussed. [Extracted from the article]

A recent study conducted by researchers at the Perelman School of Medicine at the University of Pennsylvania has found that the drug dupilumab can improve the health-related quality of life and reduce symptoms in patients with eosinophilic esophagitis (EoE). The study assessed the impact of dupilumab treatment on patients' impression of dysphagia, symptoms beyond dysphagia, and overall quality of life. The results showed that dupilumab significantly reduced the frequency and severity of symptoms, improved quality of life, and had a meaningful impact on patients. This research provides valuable insights into the potential benefits of dupilumab for EoE patients. [Extracted from the article]

A study conducted by Regeneron Pharmaceuticals Inc. has found that the drug dupilumab can provide significant and sustained improvements in disease control, symptoms, sleep, quality of life, and treatment satisfaction for adults with moderate-to-severe atopic dermatitis (AD). The study followed patients for 4 years and found that the majority of participants reported controlled disease, fewer episodes of itching, and high satisfaction with their AD treatments. These findings suggest that dupilumab may be an effective option for long-term management of AD. The study was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. [Extracted from the article]

A recent report from the University of Nottingham in the United Kingdom discusses the treatment of atopic dermatitis (AD) in children who do not respond to standard topical therapy. The study presents three cases of severe refractory AD in children who achieved disease control and improved quality of life through combined systemic therapy with dupilumab and abrocitinib. These patients had exhausted all conventional systemic therapies and experienced inadequate disease control and adverse effects with previous treatments. The combination of dupilumab and abrocitinib proved to be effective in achieving noticeable and sustained improvements in AD control. The researchers suggest that larger studies are needed to determine the long-term efficacy and safety of this treatment strategy. [Extracted from the article]

A recent study conducted by researchers at the University of Rome explores the impact of upadacitinib on atopic keratoconjunctivitis (AKC) exacerbated by dupilumab treatment in patients with atopic dermatitis (AD). The study involved six adults with moderate-to-severe AD who were switched to upadacitinib after discontinuing dupilumab due to the onset of AKC. The results showed that upadacitinib not only improved AD symptoms but also significantly reduced ocular signs and symptoms. The findings suggest that upadacitinib could be a promising alternative therapeutic option for AD patients with ocular involvement. [Extracted from the article]

A recent report from Fondazione IRCCS Policlinico San Matteo in Pavia, Italy, discusses the use of dupilumab in children and adolescents with moderate-severe atopic dermatitis (AD). Atopic dermatitis is a challenging condition to manage, and type 2 inflammation is the most common inflammatory pathway in children and adolescents with AD. Dupilumab, a monoclonal antibody, has been found to be safe and effective in managing AD by reducing skin lesions, itching, and the need for additional medications, while improving disease control and quality of life. The report emphasizes the importance of a thorough diagnostic pathway, considering the different AD phenotypes, and identifies children and adolescents with severe clinical manifestations and impaired quality of life as ideal candidates for dupilumab treatment. [Extracted from the article]

A recent study conducted by Regeneron Pharmaceuticals Inc. has found that dupilumab, a monoclonal antibody therapy, improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis (H/F AD). The study involved adults and adolescents with moderate-to-severe H/F AD who were randomized to receive either dupilumab or a placebo. The results showed that significantly more patients receiving dupilumab achieved a score of 0 or 1 on the Hand and Foot Investigator's Global Assessment, indicating improvement in disease severity. The study concludes that dupilumab is an effective systemic treatment for this challenging condition. [Extracted from the article]

A recent study conducted at the University Medical Center Utrecht in the Netherlands examined the effect of dupilumab, a treatment for pediatric atopic dermatitis (AD), on asthma and aeroallergen sensitization in AD patients. The study included 84 pediatric AD patients aged 3-17 years who were treated with dupilumab between 2019 and 2023. The researchers found that one year of dupilumab treatment resulted in a significant improvement in comorbid asthma and a decrease in aeroallergen-specific IgE levels in patients with asthma and/or allergic rhinitis. These findings suggest that dupilumab may be an effective treatment option for pediatric AD patients with asthma and allergies. [Extracted from the article]

A recent study conducted at Chung Shan Medical University Hospital in Taichung, Taiwan, examined the effectiveness of dupilumab in treating atopic dermatitis (AD) and its role in preventing the progression of the atopic march in pediatric patients. The study analyzed data from a population-based cohort and found that pediatric AD patients prescribed dupilumab had a lower risk of atopic march progression compared to those receiving conventional immunomodulatory therapy. The study concluded that dupilumab may be associated with a reduced risk of atopic march progression in pediatric AD patients. This research has been peer-reviewed and provides valuable insights into the treatment of AD in pediatric patients. [Extracted from the article]

This document provides information about a clinical trial for the treatment of atopic dermatitis, a skin condition characterized by inflammation and itching. The trial will involve participants aged 2 to 11 years and will compare the effectiveness of different medications, including upadacitinib and dupilumab. The trial is not yet recruiting participants and is estimated to be completed by June 2030. The document also includes eligibility criteria and contact information for the study. [Extracted from the article]

A new position paper from the American College of Allergy, Asthma & Immunology (ACAAI) examines the safety of administering live vaccines to patients currently being treated with dupilumab, a biologic therapy for allergic conditions. The paper concludes that it is not necessary to stop treatment with dupilumab to give live vaccines, but the decision should be made in consultation between the physician and the patient/parent. The goal of the review was to ensure that patients receiving dupilumab can also receive the full protection of recommended vaccines. The panel recommends shared decision-making between doctors and patients/parents regarding the timing and administration of live vaccines while on dupilumab. [Extracted from the article]

A recent study investigated the effects of the drug dupilumab on patients with non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD). N-ERD is characterized by hypersensitivity to NSAIDs, nasal polyps, and asthma. The study found that after 24 weeks of dupilumab therapy, N-ERD patients showed a decrease in type 2 associated cytokines and changes in transcriptomic profile during acetylsalicylic acid (ASA) provocation. However, there was no association between these changes and the development of ASA tolerance. This study provides insights into the potential benefits of dupilumab therapy for N-ERD patients. [Extracted from the article]

A recent study conducted by the University of Ottawa and The Ottawa Hospital explored the treatment of chronic kidney disease-associated pruritus, a condition that leads to decreased quality of life and is a risk factor for mortality. The researchers presented a case report of a 69-year-old female with chronic kidney disease who experienced intense pruritus. The patient was treated with dupilumab, a monoclonal antibody, and reported a significant improvement in pruritus after five months of treatment. The study suggests that further research is needed to determine the efficacy of dupilumab for treating chronic kidney disease-associated pruritus. [Extracted from the article]

A recent study conducted at the National and Kapodistrian University of Athens examined the effectiveness of dupilumab treatment for severe chronic rhinosinusitis with nasal polyps (CRSwNP) and its impact on concurrent mild to moderate asthma. The study involved six patients with severe CRSwNP who experienced significant improvements in symptoms after two weeks of dupilumab treatment. These improvements included reduced nasal polyp size, improved lung function, and enhanced asthma control. The study concluded that dupilumab effectively targets inflammation and provides significant disease control for CRSwNP patients, while also improving asthma symptoms. [Extracted from the article]

A recent study conducted by the Section of Pediatric Gastroenterology has found that dupilumab, a drug used in the treatment of eosinophilic esophagitis (EoE), is effective in adolescent patients. The study evaluated 18 patients aged 12-20 who were treated with dupilumab and found that 50% had inflammatory EoE, 22% had fibrostenotic EoE, and 28% had non-EoE eosinophilic gastrointestinal disease (EGID) with esophageal involvement. The results showed that dupilumab was highly effective in treating inflammatory and fibrostenotic EoE, with a rapid discontinuation of topical corticosteroids. However, a longer duration of therapy was required for non-EoE EGID. [Extracted from the article]

Researchers at Beijing University of Chinese Medicine have reported new findings on the treatment of severe alopecia areata with atopic dermatitis in children. The study focused on an 8-year-old girl who had experienced patchy hair loss for a year, accompanied by eyebrow loss for six months. The patient was initially treated with subcutaneous injections of dupilumab, resulting in a reduction of hair loss and improvement of atopic dermatitis symptoms. After discontinuing dupilumab, the patient began daily oral baricitinib, which led to significant regrowth of hair. No adverse reactions were observed during the treatment period. [Extracted from the article]

A recent study conducted at Vanderbilt University in Nashville, Tennessee, has found that the use of dupilumab, a human monoclonal antibody, can improve lung function in children with moderate-to-severe type 2 asthma. The study analyzed spirometry parameters in children aged 6-11 with type 2 asthma and found that dupilumab led to significant and sustained improvements in lung function measures, including forced expiratory volume and forced vital capacity. These findings are important as uncontrolled asthma in children can have long-term adverse effects on lung growth. The study was supported by Regeneron and has been peer-reviewed. [Extracted from the article]

A study conducted at Bern University Hospital investigated the effects of dupilumab, an interleukin (IL)-4/IL-13 receptor blocker, on autophagy and lysosomal degradation in patients with atopic dermatitis (AD). The researchers found that autophagy, which is important for epidermal differentiation, is impaired in AD. However, treatment with dupilumab was shown to reduce skin inflammation, restore the skin barrier, and normalize key proteins involved in autophagy and lysosomal function. This study provides further evidence that autophagy is inhibited in lesional AD skin due to lysosomal dysfunction, and that dupilumab therapy can restore dysregulated autophagy. [Extracted from the article]

A recent study conducted by researchers from the Michael G. DeGroote School of Medicine in Canada examined the real-world effectiveness and safety of dupilumab, a monoclonal antibody used to treat moderate-to-severe atopic dermatitis (AD). The study included 155 adult patients with AD who were treated with dupilumab for 52 weeks. The results showed that 64% of patients achieved a Physician Global Assessment (PGA) score of 0 or 1 at week 52, indicating a significant improvement in their condition. The study also found that dupilumab was well-tolerated, with only a small percentage of patients experiencing adverse effects. Importantly, the study included patients with other comorbidities, such as malignancy, and found no negative impact on these conditions. Overall, the study suggests that dupilumab is an effective and safe treatment option for patients with AD, including those with other medical comorbidities. [Extracted from the article]

A new report discusses the impact of Dupilumab, a monoclonal antibody therapy, on work productivity and emotional health in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The study, conducted in Northeast Italy, found that Dupilumab improved the quality of life of patients with severe CRSwNP, with positive effects on productivity and emotional well-being. The research suggests that clinicians should consider these aspects when treating patients with severe CRSwNP. The findings highlight the potential benefits of Dupilumab as an add-on treatment option for this condition. [Extracted from the article]

A clinical trial in Spain, NCT06415175, is currently underway to investigate the use of dupilumab in pediatric patients with atopic dermatitis (AD) aged 6 months to 11 years old. The trial aims to gather information on patients' characteristics, disease characteristics, prior treatments, and treatment prescription modalities. It will also evaluate the impact of treatment on quality of life and itch severity. The trial is expected to conclude by September 2026. This article provides an overview of a prospective, observational study in Spain that seeks to examine the treatment patterns and real-world effectiveness and safety of dupilumab in pediatric patients with AD. The study will assess various factors, including disease severity, treatment response, biomarkers, adverse events, and healthcare resource utilization. The study will not administer any treatment but will observe the treatment as prescribed in routine clinical practice. It is estimated that 150 patients will participate in the study, which is projected to be completed by September 2027. [Extracted from the article]

A recent study conducted at the University of Salerno in Italy explored the correlation between urinary biopyrrin levels and the severity of atopic dermatitis (AD), as well as the effects of dupilumab therapy on these levels. The study found that urinary biopyrrin levels were significantly higher in AD patients and correlated with disease severity. However, treatment with dupilumab therapy reduced these levels after 8, 16, and 52 weeks, as well as after two years of treatment. The researchers concluded that dupilumab therapy was able to improve the oxidative state in AD patients. [Extracted from the article]

A recent Phase 3 clinical trial has shown that the drug dupilumab may be effective in treating chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation. The trial found that dupilumab led to significant improvements in lung function and a lower rate of acute exacerbations compared to a placebo. The drug is the first biologic to show positive clinical outcomes in COPD. The data from the trial will be reviewed by the United States Food and Drug Administration in June. [Extracted from the article]

A recent study conducted in Sagamihara, Japan, investigated the efficacy and safety of dupilumab in Japanese pediatric patients with moderate-to-severe atopic dermatitis. The study found that dupilumab showed consistent efficacy and was well tolerated in patients aged 6 months to <18 years who had previously not responded well to existing therapies. The primary endpoint of the study was the proportion of patients with a 75% improvement in Eczema Area and Severity Index (EASI) score, and at week 16, more patients achieved this improvement with dupilumab compared to placebo. However, there was no significant difference in the proportion of patients achieving investigator global assessment (IGA) scores of 0/1 between the two groups. Overall, the study suggests that dupilumab may be a promising treatment option for Japanese pediatric patients with moderate-to-severe atopic dermatitis. [Extracted from the article]

A study conducted at the University of Bari in Italy explored the use of Dupilumab, a monoclonal antibody, as a potential therapeutic option for lichen amyloidosis (LA) in patients with atopic dermatitis (AD). LA is a type of cutaneous amyloidosis characterized by itchy papules on the skin. The study focused on a 52-year-old female patient who had been suffering from AD and LA for 27 years and had not responded to previous treatments. The patient was treated with Dupilumab, and after one year of treatment, both diseases showed complete resolution. The study suggests that Dupilumab may be an effective and safe treatment option for LA associated with AD, but further research is needed to explore its efficacy on LA and the long-term safety of the treatment. [Extracted from the article]

A systematic evaluation of the use of dupilumab for the treatment of bullous pemphigoid (BP) was conducted by researchers at the Affiliated Hospital of Chengdu University of Traditional Chinese Medicine. The study reviewed 26 articles and found that after dupilumab treatment, 66.7% of patients achieved complete remission, 25.0% had partial remission, and 5.2% showed no remission. Adverse events were reported in 16.9% of patients, with transient eosinophilia being the most common. The study suggests that dupilumab shows promise as a treatment for BP, but further research is needed to confirm its safety and efficacy. [Extracted from the article]

A recent report from the University Medical Center Utrecht in the Netherlands discusses the long-term effectiveness and safety of dupilumab, a drug used to treat moderate-to-severe atopic dermatitis (AD). The study analyzed data from over 1,200 patients, including both adults and pediatric patients, over a follow-up period of up to 5 years. The results showed that dupilumab provided sustained effectiveness in improving patient-reported outcome measures (PROMs) and had a favorable safety profile. However, certain factors such as class I obesity and itch-dominant patients were associated with less favorable treatment response. The study highlights the importance of considering patients' perspectives when evaluating the benefits of treatment. [Extracted from the article]

A study conducted at the Medical College of Wisconsin evaluated the use of dupilumab, a monoclonal antibody, in the treatment of eosinophilic esophagitis (EoE) in adolescents. The study included 18 patients aged 12-20 who received dupilumab therapy. Results showed that 50% of patients had inflammatory EoE, 22% had fibrostenotic EoE, and 28% had non-EoE eosinophilic gastrointestinal disease (EGID) with esophageal involvement. The majority of patients with inflammatory and fibrostenotic EoE exhibited a histological response to dupilumab, while a longer duration of therapy was required for patients with non-EoE EGID. [Extracted from the article]

This document summarizes a clinical trial (NCT06369467) investigating the use of linvoseltamab and dupilumab in treating severe IgE-mediated food allergies. The trial aims to evaluate the safety, tolerability, and effectiveness of the two drugs in reducing allergic reactions to different foods. The trial is not currently recruiting participants and is expected to be completed by April 2026. It is open to individuals of all genders aged 18 to 50 with a history of severe food allergies. [Extracted from the article]

A recent study conducted at Xi'an Jiaotong University in China evaluated the efficacy and safety of dupilumab in treating Kimura's Disease (KD), a rare chronic inflammatory condition. The study involved six male patients with KD who were treated with dupilumab following the same protocol as that for atopic dermatitis. The results showed significant reductions in nodule diameter, blood eosinophil count, eosinophil percentage, and total serum IgE levels after 12 and 24 weeks of treatment. One patient experienced temporary facial erythema, but no other severe adverse events were reported. The study concluded that dupilumab demonstrated effectiveness in treating KD without severe adverse events. [Extracted from the article]

A study conducted by researchers at Aix-Marseille University in Marseille, France, has assessed the real-life impact of the monoclonal antibody dupilumab on patients with severe and uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). The study, conducted in accordance with STROBE guidelines, collected data on various parameters before treatment and at 1, 4, and 12 months. The results showed that dupilumab was effective in improving the quality of life for patients with CRSwNP, as evidenced by decreased symptom scores and reduced need for oral corticosteroids. The study confirms the efficacy of dupilumab in the treatment of severe and uncontrolled CRSwNP. [Extracted from the article]

A recent study conducted in Milan, Italy, examined the effectiveness of a 2-year treatment with Dupilumab, a drug used to treat atopic dermatitis (AD), on the depressive and anxiety symptoms of patients with AD. The study found that after 2 years of treatment, patients experienced significant improvements in both their dermatological disease and comorbid depression/anxiety. However, 17.5% of patients still reported residual depressive symptoms, and 13% reported residual anxiety symptoms. The study identified several predictors of the persistence of these symptoms, including higher body mass index, lower impact of dermatological disease on quality of life, more severe depressive symptoms, and female gender. The researchers recommend that dermatologists closely monitor patients who are at a greater risk of maintaining residual psychiatric symptoms despite therapy. [Extracted from the article]

A recent report from the University of Catania in Italy discusses the use of dupilumab, omalizumab, and mepolizumab as biological drugs for the treatment of Chronic RhinoSinusitis with Nasal Polyps (CRSwNP). The report presents a Health Technology Assessment that analyzes the clinical, economic, and non-clinical domains of these drugs. The assessment found that dupilumab had a more favorable safety profile and better efficacy compared to the other biologics. Additionally, the cost per responder analysis showed that dupilumab was more economical than omalizumab and mepolizumab. This research suggests that dupilumab is a valid and preferable alternative for managing CRSwNP in the context of the Italian NHS. [Extracted from the article]

A study conducted by researchers at the University of Rome examined the efficacy and safety of dupilumab, a monoclonal antibody, in the treatment of hand eczema (HE). The study found that dupilumab was effective in achieving disease clearance in all patients, as indicated by various evaluation points throughout the study. The researchers concluded that dupilumab could be a valuable treatment option for HE, which is a chronic condition that significantly impacts quality of life and imposes an economic burden. This information may be useful for individuals seeking effective treatments for HE. [Extracted from the article]

A new report discusses research conducted at University Hospital Ramon & Cajal in Madrid, Spain, on the effectiveness and safety of Dupilumab therapy in children under 6 years of age with moderate-to-severe atopic dermatitis (AD). The study was a retrospective observational cohort study, and the results showed that Dupilumab was effective and safe in this age group. The majority of patients achieved significant reductions in symptoms, and the response was maintained in the long term for most patients. The adverse effect profile of Dupilumab in this age group was similar to that found in older children and adults. [Extracted from the article]

A recent study conducted at the Medical University of Vienna explored patient preferences for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The study focused on the use of Dupilumab, a monoclonal antibody therapy, compared to revision surgery. The results showed that 91.5% of patients who had previously undergone surgery for nasal polyps preferred Dupilumab over repeat surgery. This preference was even higher among patients with concomitant asthma or Non-steroidal Anti-inflammatory Drugs Exacerbated Respiratory Disease (N-ERD). The study suggests that Dupilumab may be a favorable treatment option for CRSwNP patients, particularly those with additional respiratory conditions. [Extracted from the article]

A recent study conducted at Bambino Gesu Children's Hospital in Rome, Italy, has found that dupilumab, a type of immunotherapy, can lead to better-controlled asthma and improved quality of life in children. The study involved children aged 6-11 years with uncontrolled moderate-to-severe asthma, and the results showed that dupilumab significantly improved asthma control and health-related quality of life. The treatment was associated with rapid and sustained improvements in asthma control, and both children and their caregivers reported significant improvements in quality of life. This research has been peer-reviewed and published in the European Respiratory Journal. [Extracted from the article]

A recent report from Vanderbilt University discusses the findings of a study on the long-term safety and efficacy of dupilumab in children with moderate-to-severe asthma. The study, called EXCURSION, included 365 children who had previously participated in the VOYAGE study. The results showed that long-term treatment with dupilumab was well tolerated and had an acceptable safety profile. The most frequently reported adverse events were nasopharyngitis, pharyngitis, and upper respiratory tract infections. This research provides valuable insights into the use of dupilumab as a potential treatment option for children with asthma. [Extracted from the article]

A study conducted at the University of North Carolina has found that dupilumab, a drug approved for the treatment of eosinophilic esophagitis (EoE), is effective in real-world settings. The study focused on patients with severe, treatment-refractory, and fibrostenotic EoE. The results showed that most patients experienced improvements in symptoms, endoscopic findings, and histologic responses after six months of treatment with dupilumab. This research provides valuable insights into the efficacy of dupilumab for a population of EoE patients who may not have qualified for previous clinical trials. [Extracted from the article]

This document provides information about a Phase 3 clinical trial investigating the use of Dupilumab in the treatment of prurigo nodularis (PN) in children and adolescents. The trial aims to assess the concentration of Dupilumab in the blood over time and the occurrence of any adverse events or anti-drug antibodies. The trial is not yet recruiting and plans to enroll 18 participants, with an estimated completion date of November 3, 2027. The trial is being conducted by Sanofi in collaboration with Regeneron Pharmaceuticals, with Sanofi being the responsible party. [Extracted from the article]

A recent report from the University Hospital Liege discusses the use of biologics in the treatment of severe asthma. The case study focuses on a 55-year-old man with severe eosinophilic atopic asthma who was treated with mepolizumab, followed by dupilumab. Both biologics were found to reduce asthma exacerbations and improve asthma control and quality of life. However, the effects on biomarkers were different, with mepolizumab controlling eosinophilic inflammation and dupilumab reducing serum immunoglobulin E and fractional exhaled nitric oxide levels. This case study highlights the potential role of eosinophils in mediating the clinical expression of asthma. [Extracted from the article]

A recent study conducted at the National Hospital Organization Tokyo National Hospital in Japan has found that low serum IL-18 levels may predict the effectiveness of dupilumab in treating severe asthma. Dupilumab is a monoclonal antibody used to treat severe asthma, but its therapeutic response varies among patients. The study found that patients with a low baseline serum IL-18 level were less likely to respond favorably to dupilumab treatment. This research provides valuable insights into predicting the effectiveness of dupilumab in treating severe asthma. [Extracted from the article]